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Abstract
This study investigated the MICs of 17 antimicrobials, for 606 toxigenic clinical isolates of Clostridium difﬁcile collected between 1993
and 2007 in Sweden. Low MIC90 values were found for metronidazole (0.5 mg/L), vancomycin (1.0 mg/L), teicoplanin (0.125 mg/L), fusi-
dic acid (1.0 mg/L), linezolid (2.0 mg/L), daptomycin (2.0 mg/L) and tigecycline (0.064 mg/L). Three isolates (0.5%) had elevated MICs for
vancomycin (4–8 mg/L); however, these isolates originated from the same patient, who was receiving long-term intravenous vancomycin
treatment. High-level clindamycin resistant isolates (MIC >256 mg/L) peaked in 1997 with 39 of 95 (41%) and out of these, 36% were
also highly resistant to erythromycin. b-Lactams such as penicillin V and piperacillin displayed MIC90s of 8 and 32 mg/L, respectively,
whereas MICs of cefuroxime were >256 mg/L for all isolates. Universal resistance to ciproﬂoxacin and levoﬂoxacin was found, and
resistance to moxiﬂoxacin increased from 4% of isolates in 2004 to 23% in 2007. Notably, these moxiﬂoxacin-resistant isolates did not
belong to the recent epidemic PCR ribotype 027, but to the pre-existing epidemic type 012 (82%), and these isolates accounted for the
majority of isolates that were resistant to clindamycin (70%), tetracycline (84%) and rifampicin (92%) as well. This investigation of
susceptibility data on clinical C. difﬁcile isolates showed variations of multiresistance to be due to a speciﬁc PCR ribotype 012,
emphasizing the importance of genotyping when evaluating emerging resistance over time.
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Introduction
Clostridium difﬁcile infection (CDI) is increasing in incidence
and morbidity, partly owing to the appearance of the C. difﬁ-
cile 027/NAP1 strain, exhibiting moxiﬂoxacin resistance [1,2],
and high levels of toxin and spore production [3,4]. Both the
suggested epidemic impact of widespread ﬂuoroquinolone
use [5] and the decline in therapeutic efﬁcacy of metronida-
zole [6] have brought more attention to active antimicrobial
susceptibility surveillance of clinical C. difﬁcile isolates [7–9].
When recommended therapies are used, in vitro resistance of
C. difﬁcile isolates has not yet been associated with treatment
failure [10], although the recent increase in the resistant
PCR ribotype 001 in the UK renews this concern [11]. The
main purpose of the present study was to obtain a compre-
hensive overview, including trends in antimicrobial suscepti-
bility or resistance in toxigenic C. difﬁcile isolates collected
from primary CDI patients in a well-deﬁned area of central
Sweden over 15 years (1993–2007).
Materials and Methods
C. difﬁcile isolates
A total of 606 clinical toxigenic C. difﬁcile isolates from
primary CDI patients were recovered by sampling the ﬁrst
consecutive 105 toxin-positive isolates obtained during the
years 1993, 1997, 1999, 2002, 2004 and 2007 at O¨rebro
University Hospital in O¨rebro County (which has approxi-
mately 275 000 inhabitants) in Sweden. Both hospital and
community isolates were included, and only primary CDI
isolates were selected, avoiding recurrences by excluding
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individuals with positive laboratory reports 6 months prior
to the actual request date. Toxin testing, culture and preser-
vation of isolates were performed as described elsewhere
[12]. The 630 primarily frozen toxin-positive faecal samples
yielded a total recovery rate of 96% (606 isolates culture-
positive for C. difﬁcile). Accordingly, 24 samples—ﬁve (1993),
ten (1997), one (1999), three (2002), three (2004) and two
(2007)—were either culture-negative (n = 5) or did not yield
isolates identiﬁed as C. difﬁcile (n = 19) when analysed by
colony appearance and agglutination (Microgen Bioproduct
Ltd, Camberley, UK).
MIC determination
Preserved C. difﬁcile isolates from all years were thawed and
cultured anaerobically on pre-reduced fastidious anaerobic
agar (FAA; Lab M Ltd, Bury, UK) at 37C for 48 h. Colonies
were subsequently suspended in nutrient broth (Oxoid Ltd,
Basingstoke, UK) to a turbidity of 4.0, using the McFarland
scale, and seeded on IsoSensitest Agar (Oxoid) supple-
mented with deﬁbrinated horse blood (5%) and 20 mg/L b-
nicotinamide adenine dinucleotide (Sigma-Aldrich, Saint Louis,
MO, USA). Initially, from 1993 to 1999, PDM agar (AB Bio-
disk, Solna, Sweden) was used, as recommended by the man-
ufacturer, but parallel use of both agar media in 1999
showed no signiﬁcant discrepancies, and the new proposed
IsoSensitest medium was used from 2002 onwards (data not
shown). Etest strips (AB Biodisk) were applied, and this was
followed by anaerobic incubation at 37C for 48 h. C. difﬁcile
ATCC 13124, Bacteroides fragilis ATCC 25285 and Enterococ-
cus faecalis ATCC 29212 were included as quality control
strains. Pharmacological breakpoints were used when avail-
able, as recommended by EUCAST (European Committee
on Antimicrobial Susceptibility Testing, http://www.eu-
cast.org/) and the Swedish Reference Group for Antibiotics
(SRGA, http://www.srga.org).
Antimicrobial agents
The following 17 antibiotics were tested: metronidazole,
vancomycin, teicoplanin, fusidic acid, clindamycin, erythro-
mycin, rifampicin, piperacillin, penicillin V, cefuroxime, cipro-
ﬂoxacin, levoﬂoxacin, moxiﬂoxacin, daptomycin, linezolid,
tigecycline and tetracycline. The more recently introduced
antibiotics, i.e. moxiﬂoxacin, levoﬂoxacin, daptomycin, linezo-
lid and tigecycline (and the older but similar tetracycline),
were only included in 2004 and 2007. Teicoplanin, cefuroxime
and penicillin V were not tested in 2004 and 2007.
PCR ribotyping
PCR ribotyping was performed as previously described [12]
and, altogether, a subset of 307 of 606 isolates (16 (1993),
32 (1997), 102 (1999), 37 (2002), 103 (2004) and 102
(2007)) were subjected to additional PCR ribotyping as well
as MIC determination.
Statistical analysis
The Mann–Whitney U-test was used when appropriate.
Results
The MIC distributions for all antimicrobials speciﬁed for each
year investigated are provided in Tables 1–3, and MIC50,
MIC90 and geometric means of MICs are given in Table 4. All
C. difﬁcile isolates were inhibited by a concentration of
£2 mg/L of metronidazole, and all but three isolates (0.5%)
also displayed vancomycin MICs of £2 mg/L (Table 1). Of the
other therapeutic alternatives, teicoplanin was the most
active agent, displaying MICs £0.5 mg/L for all isolates. Fusidic
acid also had favourable MICs (£4 mg/L), except in the case
of four isolates (0.7%) identiﬁed in 2002 and 2007 (Table 1).
For erythromycin, clindamycin and rifampicin, the prevalence
of isolates with high-level resistance (MICs >256 mg/L)
peaked in 1997 (36%, 41% and 38% of isolates, respectively,
Table 2). For rifampicin, the C. difﬁcile isolates were either
highly susceptible (MIC <0.016 mg/L, 80% of isolates) or
highly resistant (MIC >256 mg/L, the remaining 20% of iso-
lates) (Table 2). The b-lactams penicillin V and piperacillin dis-
played MIC90s of 8 and 32 mg/L, respectively (Table 4). As
expected, all C. difﬁcile isolates were resistant to the cephalo-
sporin cefuroxime (>256 mg/L, Table 2). The activity of tetra-
cycline was generally high, with 84% of isolates displaying
MICs of £0.25 mg/L, although a doubling of the numbers of
highly resistant isolates was observed between 2004 (9.8%)
and 2007 (21%). The related antibiotic tigecycline had a very
low MIC90 (0.064 mg/L), and no resistant isolate was found.
Similarly, daptomycin and linezolid had relatively low MIC90s
(Table 4). All isolates tested were highly resistant
(MIC >32 mg/L) to ciproﬂoxacin. This was also the case for
levoﬂoxacin; that is, all isolates tested in 2004 and 2007,
(Table 3) as well as 49 random isolates collected during
1993–2002, displayed an MIC of >32 mg/L (data not shown).
In contrast, only 4% (4/102) of the isolates were moxiﬂoxa-
cin-resistant in 2004, as compared with 23% (24/103) in 2007.
Discussion
This study provides a comprehensive description of the
susceptibility to 17 antimicrobials, including their MIC
distributions, of clinical C. difﬁcile isolates (n = 606) from
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1993 to 2007. These C. difﬁcile isolates were sampled
consecutively every second to fourth year from primary
CDI patients in O¨rebro County, Sweden, and this made
possible identiﬁcation of any imported or local emergence
of resistance.
All 606 isolates were susceptible (£4 mg/L, http://
www.srga.org) to metronidazole, as has been found in
previous studies [7,13], although the highest MICs (2 mg/L)
observed could cause some therapeutic concern, considering
the low gut concentrations of metronidazole [14]. Both
intermediate and/or high-level resistance to metronidazole
and vancomycin have been described in vitro [15], but the
clinical relevance in vivo remains unclear [10]. All but three
of our isolates displayed vancomycin MICs of £2 mg/L. These
three isolates were all from CDI episodes in the same indi-
vidual subjected to haemodialysis and long-term intravenous
vancomycin therapy for recurrent Staphylococcus aureus septi-
caemia. Treatment of additional pneumonia and urinary tract
infection precipitated subsequent multiple CDI episodes.
Interestingly, all three episodes were caused by PCR ribo-
type 002 (data not shown). The other glycopeptide tested,
teicoplanin, had high activity, with an MIC90 of 0.125 mg/L.
Notably, the two isolates from 1999 with the highest teicopl-
anin MIC (0.5 mg/L; Table 1) were of the same PCR ribotype
(002) as isolates that displayed elevated MICs of vancomy-
cin. Fusidic acid has been proven to be comparable to
metronidazole in clinical efﬁcacy in a few clinically controlled
CDI trials [16,17]. C. difﬁcile isolates are mostly susceptible
to fusidic acid [18], as was also conﬁrmed in the present
study. Only 0.7% of the isolates showed high-level resistance,
and all of these were from patients treated with fusidic acid
prior to the onset of CDI (data not shown). Accordingly, like
other bacteria, such as the staphylococci, C. difﬁcile may rap-
idly develop high-level fusidic acid resistance after treatment
[19].
Cephalosporins are known to have a high propensity to
precipitate CDI [20] and, as expected, cefuroxime had no
activity against the C. difﬁcile isolates tested. However, peni-
cillin V, which is known to affect Gram-positive anaerobes,
showed an MIC90 of 8 mg/L, similar to the 4 mg/L found by
Tyrell et al. [21]. Fifteen isolates from 1993 to 1999 dis-
played MICs of >8 mg/L; four of these were highly resistant
(MIC ‡128 mg/L), which could suggest the presence of a b-
lactamase. The MIC90 was higher (32 mg/L) in the case of
the b-lactam piperacillin, but a general trend of fewer resis-
tant isolates in later years (2% of isolates with MICs of
TABLE 1. Susceptibility to metronidazole, vancomycin, teicoplanin and fusidic acid of Clostridium difﬁcile isolates from primary
C. difﬁcile infection (CDI) patients in 1993–2007 in O¨rebro County, Sweden
Boxed numbers
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>16 mg/L in 2002–2007 vs. 33% for 1993–1999) was noted
(Table 2). This observation remains unexplained, since the
usage of this antibiotic has not decreased accordingly. In
2004 and 2007, however, 81% (22/27) of the piperacillin-
resistant (MIC ‡16 mg/L) C. difﬁcile isolates were of PCR
ribotype 012 (p 0.0006)(data not shown), representing the
epidemic genotype in the geographical area studied. Signiﬁ-
cant outbreaks caused by C. difﬁcile isolates that are highly
resistant to clindamycin (MIC >256 mg/L) are well known
[22], but only 10% of Swedish isolates are highly resistant
under endemic conditions [14]. Considering only highly resis-
tant isolates, we identiﬁed a peak proportion of clindamycin
resistance of 41% in 1997, and these clindamycin-resistant
isolates represented 32 of 36 of the erythromycin-resistant
isolates (36%) and all of the rifampicin-resistant isolates
(38%). This association of clindamycin, erythromycin and
rifampicin resistance was found consistently over the years
examined, and such isolates were found in 1999, 2004 and
2007 to be of PCR ribotype 012 in 89%, 69% and 79% of
cases, respectively, indicating a clonal relationship (data not
shown). Furthermore, we found this clindamycin–erythromy-
cin–rifampicin-resistant PCR ribotype 012 strain to be also
resistant to piperacillin, tetracycline and moxiﬂoxacin
(Table 3). Similar multiresistance has been described in Ger-
many [23], although the relationship with PCR ribotype 012
is not known.
In the search for new CDI treatment regimens, rifampicin-
like agents such as rifalazil have been tested, but recent
TABLE 2. Susceptibility to erythromycin, clindamycin, rifampicin, penicillin V, piperacillin and cefuroxime in Clostridium difﬁ-
cile isolates from primary C. difﬁcile infection patients in 1993–2007 in O¨rebro County, Sweden
Boxed numbers
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reports of highly resistant isolates (MIC >256 mg/L) are dis-
couraging [24]. In the present study, the C. difﬁcile isolates
were either highly susceptible or, in the case of as many as
38%, highly resistant to rifampicin (Table 2). This is similar to
the ﬁndings in some more epidemic settings, e.g. in Bristol,
UK [25], but different from the situations encountered in
other places [26]. Perhaps resistance may explain the poor
results in the past studies that have used rifampicin for CDI
treatment [27].
Fluoroquinolones have selective activity on the microﬂora
of the colon, and both selection of pre-existing and new
resistant mutants and activity against other anaerobic bacte-
ria will increase the risk of CDI. The risk thought to be asso-
ciated with moxiﬂoxacin usage has been attributed to its
extended anti-anaerobe spectrum and, thus, its propensity to
disrupt this major part of the colonic ﬂora [28]. Perhaps dec-
ades of ciproﬂoxacin use have contributed to the selection
of ﬂuoroquinolone resistance mutations in colonizing C. difﬁ-
cile strains [29]. The possibility is supported by our ﬁndings
of 2% of moxiﬂoxacin-resistant isolates as early as 1993,
before the drug was marketed (data not shown), alongside
100% ciproﬂoxacin and levoﬂoxacin resistance. Moreover,
the 4–23% increase in moxiﬂoxacin resistance among isolates
from 2004 to 2007 is explained mainly by the spread of the
multiresistant PCR ribotype 012 (Table 3). The mechanism
of moxiﬂoxacin resistance in these PCR ribotype 012 isolates
and the cause of their increase in later years is unknown. As
moxiﬂoxacin is rarely used in Sweden, the increase in this
ribotype could instead be related to co-selection by other
antibiotics or increased virulence of the actual epidemic
strain. Notably, none of the moxaﬂoxacin-resistant isolates
belonged to the current epidemic PCR ribotype 027, which
has so far been rarely found in Sweden [3].
In conclusion, the present study conﬁrms the reassuring
susceptibility data for metronidazole regarding clinical C. dif-
ﬁcile isolates, and supports its further use as a ﬁrst-line
therapeutic agent in treating CDI. The unique 15-year time-
span of consecutive sampling of isolates from a well-deﬁned
geographical area enabled us to detect variations of multire-
sistance in C. difﬁcile and unsuspected elevations of MICs of
common b-lactams agents such as penicillin V and piperacil-
lin. Finally, monitoring of ﬂuctuating susceptibility data over
TABLE 3. Susceptibility to tetracycline, tigecycline, daptomycin, linezolid, moxiﬂoxacin, levoﬂoxacin and ciproﬂoxacin in Clos-
tridium difﬁcile isolates from primary C. difﬁcile infection patients in 1993–2007 in O¨rebro County, Sweden
Boxed numbers
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time identiﬁed a high prevalence of the local multiresistant
epidemic strain, PCR ribotype 012, which was responsible
for the 2007 emergence of resistance to moxiﬂoxacin. This
again emphasizes the importance of monitoring antimicrobial
susceptibility, and also of genotyping C. difﬁcile isolates, when
evaluating any change in antimicrobial susceptibility [30].
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